ScreenerHero

HRMY Harmony Biosciences Holdings, Inc.

NAS · US · Healthcare · Biotechnology · harmonybiosciences.com
39.34USD-0.05%Mkt Cap: 2.29B $P/E: 12.69

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAK…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap2.29B USD
Enterprise Value1.78B USD
Revenue (TTM)959.90M USD
Gross Profit670.11M USD
Net Income (TTM)158.69M USD
Revenue/Share16.63 USD
Last Price39.34 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees293
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)12.69
P/E (Forward)5.89
PEG—
EV/EBITDA6.97
EV/Revenue1.86
P/S2.39
P/B2.29
EPS (TTM)3.06
EPS (Forward)6.69
52W Range
25.5277% of range43.49
52W High43.49 USD
52W Low25.52 USD
Profitability
Gross Margin77.16%
Oper. Margin34.18%
EBITDA Margin26.67%
Profit Margin18.27%
ROE18.24%
ROA12.48%
Growth
Revenue Growth30.30%
Earnings Growth88.20%
Cash Flow & Leverage
Operating CF348.20M USD
CapEx (TTM)310.00K USD
FCF Margin19.05%
FCF Yield7.98%
Net Debt-507.60M USD
Net Debt/EBITDA-1.98
Balance Sheet
Debt/Equity0.19
Current Ratio3.48
Quick Ratio3.33
Book Value/Sh17.19 USD
Cash/Share11.47 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.0 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)47.64 USD
Upside (mean)+21.1%
Target Range30.00 USD – 70.00 USD
30.00+21.1% to mean70.00
# Analysts11
Ownership
Shares Out.58.24M
Float52.09M
Insiders1.22%
Institutions99.63%
Short Interest
Short Ratio5.7d
Short % Float10.62%
Short % Out.7.95%
Shares Short4.63M
Short (prev mo.)4.14M
Technical
SMA 5039.63 (-0.7%)
SMA 20034.65 (+13.6%)
Beta1.01
S&P 52W Chg16.45%
Avg Vol (30d)934.75K
Avg Vol (10d)849.27K
Technical Indicators
RSI (14)44.9
MACD-0.0484
MACD Signal0.2859
MACD Hist.-0.3343
BB Upper42.93 USD
BB Middle40.75 USD
BB Lower38.57 USD
BB Width10.69%
ATR (14)1.322 USD
Vol Ratio (20d)0.52x